Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005450-23-LT (EUCTR)	27/08/2008	07/05/2008	A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon ß-1a (Avonex®) in a rater-blinded design - BRAVO	A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon ß-1a (Avonex®) in a rater-blinded design - BRAVO	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 13.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders	Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 INN or Proposed INN: Laquinimod Other descriptive name: Laquinimod Sodium (USAN) Trade Name: Avonex 30 microgram/0.5 ml Solution for Injection INN or Proposed INN: INTERFERON BETA -1A Other descriptive name: INTERFERON BETA -1A (Avonex®)	Teva Pharmaceutical Industries Ltd	NULL	Not Recruiting			Female: yes Male: yes	1200		Germany;Czech Republic;Bulgaria;Estonia;Spain;Italy;Lithuania
2	NCT00463710 (ClinicalTrials.gov)	June 2005	19/4/2007	Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS	Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Avonex ® monotherapy (6.0 MIU administered i.m. each week)	State University of New York at Buffalo	Biogen Idec	Completed	18 Years	65 Years	Both	150		United States
3	NCT00534261 (ClinicalTrials.gov)	November 1999	21/9/2007	Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?	Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)	Relapsing Remitting Multiple Sclerosis	Drug: Interferon beta -1a	Biogen Idec	NULL	Completed	18 Years	70 Years	Both	284	Phase 4	Belgium;Luxembourg;United Kingdom